Patents by Inventor Noubar B. Afeyan

Noubar B. Afeyan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10980845
    Abstract: Probiotic compositions containing non-pathogenic microbial entities, e.g., bacterial entities, are described herein. The probiotic compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the probiotic compositions to treat or prevent disorders of the local or systemic microbiome in a subject are also provided.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: April 20, 2021
    Assignee: Evelo Biosciences, Inc.
    Inventors: David Berry, Noubar B. Afeyan, Johanne Kaplan, Shaila Rahman
  • Patent number: 10973861
    Abstract: Provided are defined bacterial compositions for the maintenance or restoration of a healthy microbiota in the gastrointestinal tract of a mammalian subject, and methods for populating the gastrointestinal tract of a subject. Provided also are bacterial formulations for oral or gastric administration to a mammalian subject in an effective amount for prevention or treatment of a gastrointestinal disease, disorder or condition.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: April 13, 2021
    Assignee: Seres Therapeutics, Inc.
    Inventors: Noubar B. Afeyan, Mary-Jane Lombardo McKenzie, Kevin Daniel Litcofsky, David N. Cook, Matthew R. Henn, Geoffrey von Maltzahn
  • Patent number: 10925935
    Abstract: The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: February 23, 2021
    Assignee: ModernaTX, Inc.
    Inventors: Tirtha Chakraborty, Stephane Bancel, Stephen G. Hoge, Atanu Roy, Antonin De Fougerolles, Noubar B. Afeyan
  • Patent number: 10869898
    Abstract: Provided are cells containing exogenous antigen and uses thereof.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: December 22, 2020
    Assignee: Rubius Therapeutics, Inc.
    Inventors: Jordi Mata-Fink, John Round, Noubar B. Afeyan, Avak Kahvejian
  • Patent number: 10869903
    Abstract: Probiotic compositions containing non-pathogenic microbial entities, e.g., bacterial or fungal entities, are described herein. The probiotic compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the probiotic compositions to treat or prevent transplant disorders, e.g., graft-versus-host disease (GVHD), in a subject are also provided.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: December 22, 2020
    Assignee: Evelo Biosciences, Inc.
    Inventors: David Berry, Noubar B. Afeyan, Johanne Kaplan, Neal Gordon, Shaila Rahman
  • Patent number: 10864235
    Abstract: Provided are therapeutic compositions containing Ecobioticâ„¢ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: December 15, 2020
    Assignee: Seres Therapeutics, Inc.
    Inventors: Matthew R. Henn, Geoffrey von Maltzahn, Anthony Mario D'Onofrio, Kevin Daniel Litcofsky, David Arthur Berry, David N. Cook, Noubar B. Afeyan, John Grant Aunins
  • Publication number: 20200345792
    Abstract: Provided are therapeutic compositions containing microbial populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
    Type: Application
    Filed: December 21, 2018
    Publication date: November 5, 2020
    Applicant: SERES THERAPEUTICS, INC.
    Inventors: Matthew R. Henn, Kevin Daniel Litcofsky, Anthony Mario D'Onofrio, Toshiro K. Ohsumi, Mary-Jane Lombardo McKenzie, Geoffrey von Maltzahn, David N. Cook, David Arthur Berry, Noubar B. Afeyan, John Grant Aunins
  • Patent number: 10716811
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: July 21, 2020
    Assignee: Rubius Therapeutics Inc.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan Dowden, Tom Wickham, Sivan Elloul
  • Publication number: 20200172868
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating an infectious disease. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having an infectious disease.
    Type: Application
    Filed: July 19, 2017
    Publication date: June 4, 2020
    Inventors: Tom Wickham, Tiffany F. Chen, Nathan Dowden, Robert Finberg, Robert J. Deans, John Round, Avak Kahvejian, Jordi Mata-Fink, Noubar B. Afeyan
  • Publication number: 20200172867
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating cardiovascular diseases and metabolic disorders. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cardiovascular disease or metabolic disorder.
    Type: Application
    Filed: July 19, 2017
    Publication date: June 4, 2020
    Inventors: Tom Wickham, Tiffany F. Chen, Torben Straight Nissen, Nathan Dowden, Robert J. Deans, John Round, Avak Kahvejian, Jordi Mata-Fink, Noubar B. Afeyan
  • Publication number: 20200164038
    Abstract: The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.
    Type: Application
    Filed: July 29, 2019
    Publication date: May 28, 2020
    Inventors: Antonin DE FOUGEROLLES, Kristy M. WOOD, Sayda M. ELBASHIR, Noubar B. AFEYAN, Pedro VALENCIA, Jason P. SCHRUM
  • Publication number: 20200129556
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.
    Type: Application
    Filed: January 8, 2020
    Publication date: April 30, 2020
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan Dowden, Tom Wickham, Sivan Elloul
  • Patent number: 10590161
    Abstract: The current landscape for preparative chromatographic RNA purification uses reversed phase HPLC, but this technique presents many issues with process scale up and ion exchange for preparative purification has only been used for short RNAs. The invention provides preparative purification of RNA (e.g., mRNA) using ion (e.g., anion) exchange chromatography that allows for separation of longer RNAs up to 10,000 nucleotides in length via a scalable method. This method avoids problems with current techniques by using low pressure chromatography that is agreeable with existing equipment in cGMP commercial facilities, that uses aqueous-bases solutions as the mobile phase (rather than flammable of greater than 10 mg RNA/mL resin (e.g., using larger pore sorbents, >500 Angstroms, that display greater mRNA binding capacities), and that yields desired RNA salt forms for downstream formulation with no additional manipulation necessary (unlike ion pair reverse phase techniques).
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 17, 2020
    Assignee: ModernaTX, Inc.
    Inventors: William Joseph Issa, Joseph Louis Barberio, John Grant Aunins, Noubar B. Afeyan
  • Patent number: 10568910
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: February 25, 2020
    Assignee: RUBIUS THERAPEUTICS, INC.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan Dowden, Tom Wickham, Sivan Elloul
  • Patent number: 10557119
    Abstract: Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: February 11, 2020
    Assignee: RUBIUS THERAPEUTICS, INC.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, John Round, David Arthur Berry, Noubar B. Afeyan
  • Publication number: 20200016209
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.
    Type: Application
    Filed: September 18, 2019
    Publication date: January 16, 2020
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan Dowden, Tom Wickham, Sivan Elloul
  • Publication number: 20200002674
    Abstract: Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.
    Type: Application
    Filed: September 16, 2019
    Publication date: January 2, 2020
    Inventors: Avak Kahvejian, Jordi Mata-Fink, John Round, David Arthur Berry, Noubar B. Afeyan
  • Patent number: 10517897
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: December 31, 2019
    Assignee: RUBIUS THERAPEUTICS, INC.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan Dowden, Tom Wickham, Sivan Elloul
  • Publication number: 20190388473
    Abstract: Provided are cells containing exogenous antigen and uses thereof.
    Type: Application
    Filed: August 30, 2019
    Publication date: December 26, 2019
    Inventors: Jordi Mata-Fink, John Round, Noubar B. Afeyan, Avak Kahvejian
  • Publication number: 20190376034
    Abstract: Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.
    Type: Application
    Filed: August 23, 2019
    Publication date: December 12, 2019
    Inventors: Avak Kahvejian, Jordi Mata-Fink, John Round, David Arthur Berry, Noubar B. Afeyan